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A B S T R A C T
Cell-based assays to monitor antigen-specific T-cell responses are characterized by their high complexity and
should be conducted under controlled conditions to lower multiple possible sources of assay variation. However,
the lack of standard reagents makes it difficult to directly compare results generated in one lab over time and
across institutions. Therefore TCR-engineered reference samples (TERS) that contain a defined number of an-
tigen-specific T cells and continuously deliver stable results are urgently needed. We successfully established a
simple and robust TERS technology that constitutes a useful tool to overcome this issue for commonly used T-cell
immuno-assays. To enable users to generate large-scale TERS, on-site using the most commonly used electro-
poration (EP) devices, an RNA-based kit approach, providing stable TCR mRNA and an optimized manufacturing
protocol were established. In preparation for the release of this immuno-control kit, we established optimal EP
conditions on six devices and initiated an extended RNA stability study. Furthermore, we coordinated on-site
production of TERS with 4 participants. Finally, a proficiency panel was organized to test the unsupervised
production of TERS at different laboratories using the kit approach.
The results obtained show the feasibility and robustness of the kit approach for versatile in-house production
of cellular control samples.
1. Introduction
Antigen-specific T cells are key players in the clinical course of
cancer (Lu et al., 2014; Robbins et al., 2015; Rizvi et al., 2015), in-
fections (Riou et al., 2014; Ottenhoff and Kaufmann, 2012) and in-
flammatory diseases (Kleijwegt and Roep, 2013). T-cell immunity also
clinically impacts on the efficacy of in vivo gene transfer (Britten et al.,
2013), and the success of organ transplantation (Abreu and Roep,
2013). As a consequence, the number of laboratories that assess an-
tigen-specific T-cell responses in biomarker programs accompanying
the development of innovative therapies has increased over the years.
Simultaneously, T-cell assays have matured from a technology
mainly utilized in the context of basic or exploratory immunology re-
search into a tool to guide drug development and clinical research in
patients. This shift of scope has led to increased quality requirements
for assay planning, performance and analysis (Britten et al., 2012). In
particular, assay harmonization, standardization, validation and/or
quality assurance has become the focus of many research efforts (van
der Burg et al., 2011; Janetzki and Britten, 2012; Maecker et al., 2012).
The importance of implementing suitable “control reagents” to verify
protocols, reagents, instrument setup and assay analysis, as well as the
need for control samples to continuously monitor assay performance,
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was emphasized by the FOCIS Human Immunophenotyping Consortium
in 2010 (Maecker et al., 2010). Our current study introduces a novel
kit-based approach to allow for the generation of versatile control re-
agents by electroporating RNA-encoded TCRs into primary lympho-
cytes.
The Cancer Immunotherapy Immunoguiding Program (CIP) has
recently developed structured research efforts to engineer novel control
reagents that contain a defined number of functionally characterized
antigen-specific T cells. The group initially used lentiviral gene-transfer
to generate TCR-engineered references samples (TERS) (Singh et al.,
2013).
Following these proof-of-principle studies, we developed and re-
ported on an alternative method for the generation of TERS, where we
replaced lentiviral gene-transfer by RNA electroporation. This mod-
ification was introduced to overcome the limitations associated with
the need to culture and to sort stably-transduced lymphocytes, and to
increase safety measures associated with the production and shipment
of TERS (Bidmon et al., 2015). The production of RNA-based TERS also
introduced a three-part concept to apply these control reagents to
control the performance of immune assays over time. The concept is
characterized by (1) standardized and controlled manufacturing, (2)
assay-specific cut-off definition, and (3) the regular use of serial TERS
aliquots over time. TERS can be easily produced with multiple TCR
specificities (MHC-class I and II restrictions), and work across the three
most commonly applied immune assays (ELISpot, intracellular cytokine
staining and MHC-multimer staining). Most importantly, their regular
use could sensitively detect typically observed deviations in cell quality,
reagent stability, hardware settings, and analysis of assay results. One
shortcoming of the TERS technology is that the generation of a large
number of aliquots is manageable, the storage and distribution of TERS
batches to laboratories worldwide is associated with high costs and
logistical effort as the transport needs uninterrupted temperature con-
trol. This fact makes it difficult to scale-up the technology, an essential
step which would be required for their broader use.
The current study aims to overcome this limitation and introduces
an easy-to-use novel kit-based approach to allow for the generation of
versatile control reagents at peripheral sites by electroporation (EP) of
RNA-encoded TCRs into primary lymphocytes. The kit is based on the
shipment of quality-controlled TCR RNA and a standardized user
manual for the manufacturing of TERS at the site of their use. In ad-
dition, GFP RNA and a manual are provided for the initial set-up of the
lab-specific EP device. Prior TERS application, frozen aliquots of the
generated TERS batch are used to define the intensity of the antigen-
specific signal and cut-off values reflecting an acceptable signal range
for the particular assay. TERS are then ready for continuous use to
control the performance of the assay (Fig. 1). In this study, we have
generated data showing that the proposed kit-based approach is com-
patible with most commonly used EP devices. Also stability studies
were conducted for the TCR-encoding RNA, which is the critical
starting material for the in-house generation of TERS. Finally, a
proficiency panel was performed to confirm that investigators that had
never used the kit before can utilize it to generate TERS batches that
work in their locally-established assay protocols.
2. Materials and methods
2.1. Optimization of EP settings
Six commonly used devices from 4 vendors were extensively tested
over a broad range of settings to optimize device-specific EP conditions
for the generation of TERS: ECM830 from BTX/Harvard Apparatus
(BTX™/Harvard Apparatus Inc., Holliston, MA), Multiporator from
Eppendorf (Eppendorf AG, Hamburg, Germany), Genepulser II and
Xcell from Bio-Rad (Bio-Rad, Laboratories Inc. Hercules, CA),
Nucleofector II and Amaxa 4D from Lonza (Lonza, Verviers, Belgium).
By Ficoll (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) density
gradient centrifugation isolated PBMCs from buffy coats obtained from
consenting, HLA-A*02-positive donors (Transfusion Center, University
Medical Center, Mainz, Germany) were electroporated using GFP-RNA,
chimeric NY-ESO-1157-168-, wild type (wt) human Influenza58-66- or
chimeric tyrosinase368-376-specific α+ β TCR RNA (in-house produc-
tion; all class I restricted). For the EP using GFP-RNA or the Flu-TCR
RNA, 2.0–10.0 μg RNA (per TCR chain) and 1.0–5.0×106 PBMCs were
used. Testing the tumor associated antigen (TAA)-TCRs specific for NY-
ESO-1 and tyrosinase (including Flu-TCR only for BTX), EP conditions
analog to the TERS production process were used, testing 10.0–75.0 μg
RNA (per TCR chain) and 10.0–60.0×106 PBMCs. Voltages and pulse
lengths in the ranges of 200 V–1000 V and 0.05ms–15ms/
150 μF–1500 μF were tested respectively with square or exponential
pulse form and variable number of pulses. The EP volume 20 μl–250 μl
differed based on the used EP cuvette: Bio-Rad - 4mm (Bio-Rad), BTX
(BTX/Harvard Apparatus) and Lonza Nucleocuvette Vessel/Stripe
(Lonza). Different EP media were tested including X-vivo (Lonza), CTL-
Wash supplement medium (CTL, Shaker Heights, OH), OPTI-MEM I
(Gibco/Life Technologies, Carlsbad, CA), Bio-Rad-Genepulser EP Buffer
(Bio-Rad) and BTXpress High Performance EP Buffer (BTX/Harvard
Apparatus), partially in accordance with manufacturer's instructions.
The Nucleofector solution and the human T cell Nucleofector solution
were included in the EP kit provided by Lonza. The viability of trans-
fected T cells was determined by using the ViaCount Assay (Merck
Millipore, Darmstadt, Germany). The cells were stained with the
Guava® ViaCount Reagent and analyzed on the Guava® easyCyte 5HT
flow cytometry system.
A range of experiments were performed (detailed described in the
results´ part and summarized in Table 1) to identify the optimal EP
settings to achieve maximum TCR expression and maximum viability of
transfected T cells. This initial strategy enabled us to define rough
parameters by testing large ranges of voltages and pulse lengths re-
sulting in detectable signals and acceptable cell viabilities (see read out
method below). The second step was to further optimize the rough
Fig. 1. Concept and design of the TERS Immuno-
Control Kit. The provided kit contains an antigen-
specific, quality-controlled TCR RNA and a device-
specific user manual for the manufacturing of one
TERS batch (highlighted in grey). The generated
TERS batch is then to be tested to define the batch
and assay specific signal including the cut-off values.
The TERS aliquots can be repetitively applied as
assay performance control in parallel to the test
material or the patient samples. Additionally, a GFP
RNA and a protocol for the initial set-up of the lab-
specific EP device will be provided to support the
fine-tuning of optimal EP parameters on the locally
available EP device prior TERS generation. This op-
timization step would have to be performed only
once when starting using the new technology (indicated by “*”).
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parameters to reach the maximum achievable increase in transfection
efficiency and viability. In a third step, single parameters within the
defined parameter ranges were fine-tuned. Finally, the optimized set-
tings were used to test the EP on high number of cells and large amount
of RNA including the use of TAA-specific TCR RNA for the TERS pro-
duction process. This optimization strategy was adapted specifically to
each device based on the manufacturer's recommended material (buf-
fers, cuvettes), device-specific limits of settings (max./min. voltage,
pulse form: exponential (pulse length: μs or ms) or square (capacitance:
μF), number of pulses) and defined pulse forms.
2.2. RNA stability study
In this study, we used a chimeric TCR construct with a murinized
constant domain and a human variable domain of the HLA-A*02-re-
stricted TCR specific for the epitope NY-ESO-1157-165 (SLLMWITQC).
The original human wild-type construct was kindly provided by T.
Schumacher (The Netherlands Cancer Institute, Amsterdam, The
Netherlands). A large-scale TCR RNA α and β batch was manufactured,
based on “fed-batch” T7 transcription and followed by immuno-mag-
netic bead separation using DynaMag™ magnets (Invitrogen/Life
Technologies) in combination with Dynabeads® MyOne™ Carboxylic
Acid (Invitrogen). The purified and qualified RNA was aliquoted in
10 μg aliquots for quality control testing and determination of RNA
concentration, and also in larger aliquots containing 35 μg RNA per
chain for in vitro testing. From each RNA concentration several aliquots
were stored at −80 °C, at 2–8 °C and at RT to assess degradation pro-
files. Single 10 μg RNA aliquots of each storage condition were used
after 0, 3, 6, 12, 18 and 24months of storage to test RNA integrity using
the Agilent RNA 6000 Nano Assay (Agilent Technologies, Inc., Santa
Clara, CA) and the Agilent 2100 Bioanalyzer System (Agilent
Technologies, Inc.). In parallel, the RNA concentration of each aliquot
was tested using the NanoDrop 2000c Spectrophotometer (Thermo
Scientific, Wilmington, DE). In addition, the TCR surface expression on
CD8+ T cells was tested after applying these TCR RNA's for the EP of
PBMCs using the ECM 830 Square Wave Electroporation System (BTX/
Harvard Apparatus) at the same temperature and storage time points.
2.3. Quantification of TCR expression
The in vitro testing was performed by the EP of freshly isolated
PBMCs with the TCR RNA on the basis of the optimized standard pro-
cedure for the generation of TERS, also using 20× 106 PBMCs and
35 μg TCR RNA of α and β, which was described in detail in our pre-
vious publication (Bidmon et al., 2015). After over-night culture, the
TCR-transfected cells were harvested to check the recovery and viabi-
lity of cells using Erythrosin B (Sigma-Aldrich, Saint Louis, MO).
1× 106 cells were used for flow cytometry to detect TCR surface ex-
pression on CD8+ T cells using MHC-peptide dextramer. NY-ESO-1157-
165 APC dextramer (Immudex, Copenhagen, Denmark) staining was
performed based on the staining protocol described in Bidmon et al.,
2015. Deviating from this protocol, the viability staining was performed
prior to dextramer staining using Fixable Viability Dye eFluor506
(65–0866, eBioscience, San Diego, CA). Additional antibodies including
CD8 Brilliant Violet 421 (clone RPA-T4, BD Biosciences, San Jose, CA)
and CD4 APC-Cy7 (clone: SK3, BD Biosciences) were applied after
dextramer staining. The samples were acquired on the Canto II (BD
Biosciences) and the FCS files were analyzed with FlowJo software
version 7.6.5. (TreeStar, San Carlos, CA). The gating was as follows:
singlets (FSC-H vs. FSC-W), living cells (FSC vs. Live/Dead), lympho-
cytes (FSC vs. SSC), CD8+ (CD4+ vs. CD8+), % Dext+ of CD8+ (CD8+
vs. Dext+).
2.4. Proficiency panel
Six experienced labs from four European countries (Germany, UK,
Denmark, The Netherlands) participated in a proficiency panel. For the
first part, each participant received sets of 2 vials of a centrally man-
ufactured TERS, each containing 5×106 cells shipped on dry ice. The
first vial of each set contained cells from a sub-batch with a low fre-
quency of NY-ESO-1157-165-specific T cells (TERS#33 1:100 dilution),
which was generated by transfecting PBMCs from a HLA-A*0201 po-
sitive healthy donor with a chimeric NY-ESO-1157-165 TCR specific for
the SLLMWITQC epitope. The second vial contained cells from a sub-
batch lacking NY-ESO-1-specific T cells (TERS#33 negative fraction).
The task of the first part was to thaw the two vials of one set of the
centrally provided TERS and to stain the two samples with the two
provided dextramers: A*0201 NY-ESO-1 (SLLMWITQV)-APC and
A*0201 Negative control (irrelevant)-APC in one experiment (Test 1,
T1). Then we asked the participants to repeat the experiment using the
second set of vials on a different date (Test 2, T2), to show reproduci-
bility of the results generated with the TERS. The labs were allowed to
use their locally established staining protocol for the experiments with
two mandatory restrictions: use 5 μl of dextramer and incubate for
10min at RT and the staining cocktail should include at least one CD8
antibody, one CD4 antibody and a dead cell dye. All labs were allowed
to add additional markers and to perform the analysis of data de-
pending on their local preferences.
The second part, implemented the TERS kit approach for the pro-
duction of the TERS at peripheral sites, as depicted under user part in
Fig. 1. Two tasks (Initial set-up of EP device (2A) & Manufacturing of
TERS (2B)) had to be performed. For part 2A, each participant received
GFP-RNA and a protocol to set up tailored EP parameters on the lab-
specific EP device prior to TERS manufacturing. For part 2B, including
the production of the internal TERS batch, chimeric NY-ESO-1157-165
D1-capped TCR RNA was provided. All participants also received two
HLA-peptide dextramers: an irrelevant dextramer (Negative control
dextramer) and a specific NY-ESO-1157-165 dextramer.
Part 2A aimed at establishing and fine tuning the EP settings, such
as voltages (V), pulse length (ms) or capacitance (μF) and the number of
pulses on the locally available, lab-specific EP device, based on the
provided optimization protocol using GFP-RNA and the recommended
EP parameters that were pre-tested on an identical EP device by the
central lab. The aim was to achieve maximal TCR-expression levels
(> 80% GFP+ in CD8+) with maximal viability of transfected CD8+ T
cells (> 90%). The task of part 2B was to use the device-specific, op-
timized EP settings and the provided standard protocol for the manu-
facturing of TERS to generate and test locally-produced TAA-specific
TERS. For this purpose, centers used freshly isolated, A*0201-positive
PBMCs, transfected with the provided A*0201-restricted, NY-ESO-1157-
165-specific TCR RNA (SLLMWITQC) and mixed them with untouched
PBMCs (negative fraction) of the same donor in a pre-defined ratio of
1:100 NY-ESO-1+ of CD8+. Aliquots of the produced TERS batch and of
the negative fraction were frozen and stored in liquid nitrogen. One
aliquot of the 1:100 TERS batch and the negative fraction represent one
set of the internal TERS. The two samples of one set were tested in
dextramer staining experiments on two independent time points (T1
and T2) using the provided dextramers (detailed testing procedure was
described above for the central TERS).
Finally, participants had to complete a questionnaire containing
basic information regarding the cell quality, the staining and analyzing
procedure, as well as a report form showing the resulting dot plots and
the number of lymphocytes, CD8+, and CD8+ Dext+ cells as well as the
% of Dext+ within the CD8+ population.
3. Results
3.1. Utility of several EP devices for TERS manufacturing
It is known that different EP devices, even the same type from the
same company may perform differently and thus it is required to op-
timize the EP parameters for each locally available device. A wide range
N. Bidmon et al. Journal of Immunological Methods 458 (2018) 74–82
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of different EP devices are available on the market and used worldwide.
Therefore a survey asking peers for their in-house EP devices was
performed leading to the identification of six most commonly used
devices from 4 vendors: Harvard Apparatus - BTX ECM830, Eppendorf -
Multiporator, Bio-Rad - Genepulser II and Xcell and Lonza -
Nucleofector II and Amaxa 4D. To assess whether commonly used EP
devices are suitable for the generation of TERS and to narrow down the
range of settings under which TERS with optimal properties may be
manufactured, a series of tests were conducted to pre-define EP settings
on six commonly used devices with the aim to achieve maximum TCR
expression levels (benchmark of> 80% TCR+ of CD8+) and maximum
viability of transfected CD8+ T cells (benchmark>90% viability).
First, we extensively tested the ECM 830 from BTX/Harvard
Apparatus (Table 1; 1st column). We applied broad range of voltages,
pulse times and pulse numbers (fixed square pulse form) with variable
time intervals. Additionally, different EP buffers and cuvettes were
used. We tested a range of cell numbers and RNA amounts in a matrix.
A detailed overview of selected optimization results is shown in Sup-
plementary Fig. 1A. A voltage of 500 V and one pulse with a length of
3ms using the BTX EP buffer yielded high transfection efficiencies (TEs)
of up to 97.3% antigen-specific CD8+ T cells with high viability up to
96.0% (Fig. 2; 1st column).
Subsequently, a similar test matrix was used for the Multiporator
from Eppendorf (Table 1; 2nd column). But pulse length (limited to
500 μs) with fixed square pulse form and the EP buffers differed from
that of the BTX system, precluding the simple transfer of the settings
that had been established on the ECM830. The voltages using the
Multiporator were increased up to 1000 V. Initial tests were performed
using low amounts of GFP-RNA (10 μg) with 5× 106 PBMCs, whereas
the defined optimal cell number of 20× 106 and RNA amount of 30 μg
of each TCR-chain was used for final tests. Based on manufacturer's
recommendations the provided EP cuvettes and buffer system were
tested for our applications (Supplementary Fig. 1B). The optimal
parameters for TERS generation were 700 V, one pulse of 500 μs using
the hypo-osmolar EP buffer (optimum 1), resulting in 89.7% Dext+ of
CD8+ and 94.6% viable cells (Fig. 2; 2nd column). When voltage was
changed to 800 V and the isoosmolar EP buffer was used (optimum 2),
the TE was 88.1% Dext+ of CD8+ T cells and 97.4% viable cells
(Supplementary Fig. 1B).
The results of the Genepulser II from Bio-Rad are shown in Table 1
(3rd column). We applied 3 different voltages (400 V, 450 V and 500 V),
one capacitance of 250 μF (based on our experiences with this device)
with fixed exponential pulse form and compared 3 media: X-vivo, OPTI-
MEM I and Bio-Rad-Genepulser EP Buffer (Supplementary Fig. 1C). A
maximum TE of 78.3% with a high viability of 92.0% of transfected T
cells was achieved with 400 V, one pulse of 250 μF in X-vivo medium
(Fig. 2; 3rd column).
The Genepulser Xcell from Bio-Rad allowed to set a large variety of
parameters regarding voltage, pulse forms: exponential (capacitance) or
square (pulse length) and EP buffers that could be tested (Table 1; 4th
column). A large series of tests were run based on our findings with the
previous devices and published data, as detailed in Supplementary
Fig. 1D. Three different EP settings led to a maximum TE>90% and
maximum viability of T cells> 90% that were finally set to 400 V,
10ms, 1 pulse (optimum 1) or 1000 V, 0.5 ms, 1 pulse (optimum 2) or
450 V, 3ms, 2 pulse (optimum 3) using square pulse form and OPTI-
MEM I to achieve>90% cell viability and > 90% antigen-specific
CD8+ T cells for all three settings (Fig. 2; 4th column and Supple-
mentary Fig. 1D).
The two EP systems Nucleofector II and Amaxa 4D, provided by
Lonza, did not allow a flexible, user-driven choice of parameters.
Therefore, only a limited optimization series could be performed
(Table 1; 5th and 6th column), applying defined buffers and EP cuvettes
that restricted EP volume and thus the number of cells to be transfected.
Pre-defined, encoded programs were recommended and specified by
the manufacturer (Supplementary Fig. 1E, F). The performed
Fig. 2. Optimized EP settings for 6 commonly used EP devices. By the use of optimized EP settings (lower part) for each of the tested EP devices a high viabi-
lity> 90% of transfected T cells (upper part) and a high transfection efficiency>90% NY-ESO-1+ of CD8+ cells (middle part) was achieved for almost each EP
device. Lower viabilities of 78–79% and transfection efficiencies of 61–62% NY-ESO-1+ of CD8+ were reached for the Lonza devices.
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experiments resulted in TEs of< 63% and viabilities of ~80% using
2.5 μg of the TCR RNAs, adapted to the recommended number of cells
of 1× 106 PBMCs to be used for one EP. With GFP RNA a maximum TE
of 90% (Fig. 2; 5th and 6th column) was reached. In preparation for the
production of TERS, a reduced TE can be compensated by spiking
higher numbers of TCR-transfected T cells into non-transfected cells in
order to obtain the desired frequency of antigen-specific T cells. The
limited number of cells that can be electroporated will make the pro-
cedure more complex than with other EP systems.
In summary, a set of optimized EP settings for 6 commonly used EP
devices was established that lead to high cell viability (> 90%) and
high TCR RNA transfection efficiency (> 60% of CD8+ T cells) (Fig. 2).
These data sets are now available to guide the fine-tuning of settings on
the lab-specific device to effectively generate high quality TERS.
3.2. RNA stability and shelf-life
We conducted an extended TCR RNA stability test, testing 30 μg
aliquots of a chimeric HLA-A*0201-restricted TCR RNA specific for NY-
ESO-1157-165 (α- and β-chain) stored at −80 °C, 2–8 °C (accelerated
instability), and RT (forced instability) to assess the degree of de-
gradation of TCR RNA over time. At different time points RNA integrity
was assessed using the Bioanalyzer and functionally by transfection of
the RNA into freshly isolated PBMCs and subsequent analysis of TCR
cell surface-expression levels using dextramer staining.
The results in Fig. 3 show a high stability of NY-ESO-1157-165 TCR
RNA up to 24months of storage at −80 °C. The integrity ranged from
85% to 92%, reflecting the high stability of the RNA molecules over
time. The final detected signal of 91% antigen-specific CD8+ T cells is
slightly reduced after 24months compared to the signal intensity de-
tected at the very beginning using freshly produced TCR RNA (95%
antigen-specific CD8+ T cells, left dot-plot). The RNA stability was
significantly reduced after 12 and 24months of storage at 4 °C showing
integrity of 79% and 72%, respectively. Still, the TCR RNA retained
high functionality as shown by an only slightly decreased TE of 87%
after 24months. These are similar levels that are comparable to the TE
of 95% obtained with the fresh RNA. In contrast the stability of the TCR
RNA stored at RT was significantly decreased (integrity 70%) after
2months of storage (TE was not tested; data not shown) which was an
expected finding. In summary, the stability data from this study will
allow guaranteeing TCR RNA stability at −80 °C and 2–8 °C for at least
24months of storage. The data from this study will allow assigning
appropriate shelf-life to the TCR RNA to the future immuno-control kit,
facilitating the shipment conditions at 2–8 °C and defining the handling
and storage of the RNA upon receipt.
3.3. TERS kit approach testing in a workshop
We conducted a workshop to test the TERS production process with
non-experienced investigators under the developer's guidance. Four
investigators from Leiden (The Netherlands), Southampton (UK) and
two labs from Tuebingen (Germany), all experienced in T-cell assays,
participated. The aim was to generate a HLA-A*0201-restricted TERS
specific for the NY-ESO-1157-165 SLLMWITQC epitope. The participants
were divided into two groups (#1 and #2) and generated two different
TERS batches (#1 and #2) from freshly isolated PBMCs from the same
donor. The groups generated their own TERS batch using the in-house
available EP device (BTX ECM830) following the centrally provided
production manual stating a defined number of PBMCs and applying
the same TCR RNA. The TCR-transfected T cells of each group were
cultured at 37 °C as two independent positive fractions, whereas the
untouched PBMCs of the donor kept as one negative fraction at RT for
both groups. After overnight culture, the TCR+ T cells and the negative
fraction were analyzed via NY-ESO-1(157-165) dextramer staining to
determine the TE and the background signal. In parallel, the viability of
both fractions was tested. Supplementary Fig. 2 summarizes these re-
sults. The TCR-transfected T cells of both positive fractions showed a
high viability of 94% (#1) and 93% (#2), and TEs of 79.0% (#1) and
66.0% (#2) NY-ESO-1(157-165) -specific CD8+ T cells. The highly viable
T cells (91%) of the negative fraction displayed a background of 0.03%
NY-ESO-1(157-165)-specific CD8+ T cells. Each group prepared diluted
TERS batches and defined their final NY-ESO-1-batch-specific signal
Fig. 3. RNA stability study to prove RNA half-life at different storage conditions over a period of time. The stability of the NY-ESO-1 TCR RNA, stored at −80 °C
(closed circle) or at 2–8 °C (open circle), was proved by the determination of the integrity [%] shown on the y-axis in the diagram and depicted as line-graph in the
upper part of the figure. The tests were performed on independent time points after 0, 3, 6, 12, 18 and 24months (x-axis of the diagram) of storage. The NY-ESO-1
TCR expression on CD8+ T cells is depicted as dot plots (NY-ESO-1 dextramer staining on the y-axis and CD8 on the x-axis) and integrated in the graph (lower part of
the figure) and visually linked to each data point of integrity measurements. The corresponding transfection efficiency [% NY-ESO-1+ of CD8+] for each time point is
shown in the boxes on the upper left of each dot plot.
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aiming a moderate signal of ~0.5% (#1) and a higher signal of ~1%
(#2). Measured by flow cytometry, both TERS dilutions show high
viability of 86.0% (#1) and 88.0% (#2) and a NY-ESO-1(157-165) -spe-
cific signal of 0.67% (#1) and 0.90% (#2) CD8+ T cells.
3.4. TERS kit approach in a proficiency panel testing
In this proficiency panel (CIMT Immunoguiding Program (CIP)
panel, CIP_ID17_2013_RSKITMUL/E) we tested how the TERS kit ap-
proach performs at peripheral sites. For the first part of the proficiency
panel, a centrally manufactured TERS was provided as a “positive”
control ensuring control of how a pre-manufactured TERS performs if
tested in the hands of different investigators using different staining
protocols. In the second part of the proficiency panel all participants
generated their own TERS, making use of locally available EP devices
and their optimized and fine-tuned EP settings established by using GFP
RNA. Both the centrally provided as well as the peripherally manu-
factured TERS were tested in parallel at two independent time points to
assess the reproducibility of the results. 6 labs (including the 4 labs
having participated to the workshop) participated to this proficiency
panel.
First, the participants used the provided TERS in their locally-es-
tablished staining protocols at two independent time points (T1 and
T2). The overview of the results (Supplementary Fig. 3), presenting dot
plots of the 100-fold diluted TERS (T1) stained with the NY-ESO-1(157-
165) -specific dextramer (1st row) or the irrelevant dextramer (2nd row),
and the percentage of NY-ESO-1(157-165)-specific CD8+ T cells on both
time points (T1 and T2). The participants successfully detected clearly
clustered dextramer-positive populations with robust and highly com-
parable NY-ESO-1(157-165)-specific CD8+ T cell signals of 0.55–0.76%
(T1) and 0.5–0.8% (T2), indicated by a low intra-lab variation
(CV < 11.6%). When focusing on the results generated across institu-
tions, we found a high concordance of reported frequencies character-
ized by a low CV of 12.3% (T1) and 17.0% (T2). The low non-specific
binding of irrelevant dextramers is indicated by dextramer-positive
CD8+ T cells with frequencies below 0.06% (mean≤ 0.02%). These
data confirmed that there is a high concordance of results generated
within and across institutions irrespective of multi-user diversity, as
published previously for centrally manufactured TERS (Bidmon et al.,
2015).
Considering the manufacturing of internal TERS, each lab electro-
porated 20×106 cells of freshly isolated PBMCs from a HLA-A*0201-
positive buffy coat donor, based on the optimized lab-specific EP set-
tings (Supplementary Fig. 4). The cells were cultured at 37 °C in the
incubator as positive fraction and the non-transfected T cells were
stored at RT as negative fraction (based on the optimization experi-
ments for the standardized manufacturing of TERS described in Bidmon
et al., 2015). On the next day, both fractions were tested for viability
and the frequency of NY-ESO-1(157–165)-specific CD8+ T cells (Supple-
mentary Fig. 4). The fractions of lab 01 and lab 14, using the ECM830
(BTX/Harvard) Apparatus (450 V, 8ms, 1 pulse and 500 V, 3ms, 1
pulse) displayed>90% viability and TEs>92% in the positive frac-
tion. Three labs (labs 08; 09; 11) used the Genepulser II from Bio-Rad
applying EP settings (400/450 V, 250 μF, 1 pulse), very close to the
recommended settings. Their fractions showed> 90% viability and a
TE of ~83% for lab 08 and 09, and of ~67% for lab 11. Finally, the
Genepulser Xcell from Bio-Rad was used by Lab 50 (450 V, 5ms, 2
pulse) resulting in a viability of 71% of transfected T cells (97% for the
negative fraction) and a TE of 54%.
Altogether, the background of 0.03–0.29% was low, as detected by
staining of the negative fraction with the specific dextramer, and the
average cell viability was 87% for the 100-fold diluted TERS batch and
the negative fraction (data not shown).
The overview of the results from all laboratories (Fig. 4), showing
dot plots of the NY-ESO-1(157-165)-specific locally produced TERS
stained with the specific (upper row) and the irrelevant (lower row)
dextramer. Thus, all 6 labs were able to generate TERS without su-
pervision using the provided TCR RNA and the manufacturing protocol.
The clustering of events differed across labs, e.g. ID11 showed a more
spread population than the other labs, which is based on different
staining protocols and analyzing methods. Differences of the fre-
quencies across labs between 0.4% and 1.5% (T1) and 0.3% and 1.3%
(T2) NY-ESO-1+ of CD8+ were detected. The mean NY-ESO-1-specific
response of 0.98% (T1+T2) is highly comparable to the 1.0% goal
frequency. The differences between independent batches were not an
unexpected finding. But this variation across labs is irrelevant, as the
variation across aliquots of one in-house produced batch is low. The
reproducibility of the NY-ESO-1-specific signal was assessed by the
staining on two independent time points (T1 and T2). Each lab detected
robust NY-ESO-1- specific responses at both time points that were
highly comparable, indicated by a low inter-assay (intra-batch) varia-
tion. 2 of 6 labs showed a variation of 10% and 20%, whereas 4 of 6
labs generated results with a variation<10%.
The unspecific background of self-made TERS, as detected by the
staining with an irrelevant dextramer was low (< 0.07%) in all tests.
These results demonstrate that the TERS technology is a robust
system applicable to various staining protocols and multi-user diversity.
4. Discussion
The recently introduced TERS technology is an easy to use and ro-
bust tool to generate reference samples for commonly applied T cell
assays (Bidmon et al., 2015). Here we show that a kit-based approach,
providing stable RNA, that can be manufactured in large quantities and
be shipped at 2–8 °C, rather than electroporated TCR-engineered cells
now allows each laboratory to manufacture their own TERS. With this
kit we provide a novel tool for the generation of reference samples for T
cell assays. Alternative technical solutions proposed in the past utilized
cryopreserved TILs, Jurkat cells and PBMCs from healthy donors or
cancer patients with pre-existing T cell responses against recall antigens
to be used to control T cell assay performance (Xu et al., 2008). Also
lyophilized, prelabeled PBMC samples (Stebbings et al., 2015; Wang
et al., 2015) or specially processed and cryopreserved PBMCs (Garcia
et al., 2014) were provided to be used as standard controls. So far none
of the available alternatives had the same favorable properties as TCR-
engineered PBMCs that best mimic assay signals from endogenous T
cells. In addition to the superior function, the TERS kit offers ad-
vantages compared to the previously described concepts. Most im-
portantly, the transport costs for the shipment of RNA instead of cell
material are considerably lower, which supports scalability and broad
adoption. An additional advantage is that all investigators can control
the size of the antigen-specific signal (low, medium and high frequency
responses can be achieved) at will to generate a reference sample that is
tailored to the specific user requirements.
In this study, we showed that the advanced kit-based TERS ap-
proach is compatible with commonly used EP devices, which makes it a
broadly applicable technology (Fig. 2). The initial optimization studies
were performed by adapting EP settings specifically to each device and
allowed to narrow down the choice of settings for participants in the
proficiency panel. The EP systems from Harvard Apparatus, Eppendorf
and Bio-Rad offered a wide range of optimization strategies, giving the
possibility to freely combine all required parameters and finally leading
to perfectly optimized EP settings resulting in maximum TEs (> 80%)
and maximum viabilities (> 90%). Whereas the Lonza EP systems of-
fered less flexibility by only providing defined programs with concealed
parameter sets to be used with manufacture-specified kit components
and pre-defined procedures finally showing reduced TEs and viabilities.
Additionally, the limited number of cells that can be electroporated in
one reaction will make the procedure more complex than with other EP
systems. Within the TERS production process a reduced TE of the TCR
which may result from the use of suboptimal EP conditions or from
inefficient RNA transfer on a given day, or due to donor variation can
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easily be compensated by spiking higher numbers of TCR-transfected T
cells into non-transfected cells in order to obtain the desired frequency
of antigen-specific T cells within the final TERS batch.
We showed that the genetically and chemically engineered RNA is
characterized by its high stability over a long period of time (Fig. 3).
The generated data showed that the RNA as the key element of the kit is
a highly robust reagent that is perfectly suited for the shipment even at
2–8 °C which is easy and cost effective. Long-time storage up to
12–24months did not have a significant effect on RNA stability and
functionality. Even slightly reduced integrities or loss of RNA con-
centration that we observed at the end of the monitoring period did not
cause a significant decrease of the TE. This finding reflects the robust-
ness of the standardized method based on RNA transfection by EP and
the specifically engineered RNA constructs. The results of the profi-
ciency panel demonstrate that the TERS technology provided with the
kit format is transferrable to a variety of labs, and works in the hands of
different experienced investigators and across multiple protocols
(Fig. 4). The differences of the final antigen-specific frequencies be-
tween independent batches, especially across labs were an expected
finding. Variations of the manufacturing process are mainly driven by
the resulting TCR transfection levels, as well as on the precision of cell
counts and the spike-in process. This variation across labs is acceptable,
as the variation across aliquots of each batch is not affected. Even the
batch-to-batch variation within one lab is acceptable because each
batch is newly validated for its signal intensity and assay-dependent
signal variation (definition of assay- and batch-specific cut-off values).
The envisioned, RNA-based kit can contain quality-controlled TCR
RNA specific for selected viral or tumor-associated antigens. A detailed
manual would describe the manufacturing process in general and pro-
vides step-by-step instructions for EP and cell processing. The same kit
could also contain a protocol for the initial set-up of each user's EP
device as well as the required GFP RNA for the establishment, testing
and potential optimization of EP settings (Fig. 1). Based on TCR RNA as
critical starting material all investigators can control the number of
spiked TCR+ T cells over a range of frequencies and define the intensity
of the antigen-specific signal, the number of frozen cells per aliquot,
and the number of aliquots per batch. Each investigator is free to adapt
parts of the production process to local preferences and conditions and
is able to use own protocols for the isolation of PBMCs, freezing and
thawing of cells, MHC-multimer staining, or functional read-outs. In-
itially, the batch-specific signal size and the acceptable signal range
need to be defined (definition of cut-off values) for the lab-specific
Fig. 4. Proficiency Panel - Multi-user testing of the TERS kit approach (part 2B): 6 participating labs used their own EP device and the lab- and device-specific,
optimized EP settings to generate TERS in a defined dilution of 1:100 with an expected signal of ~1% NY-ESO-1 Dext+ of CD8+, using the provided kit components:
the NY-ESO-1 TCR RNA, the EP-device-specific manufacturing protocol and dextramers. The upper part of the figure shows dot plots of the staining results of one
time point (T1) using the specific NY-ESO-1 dextramer and an irrelevant dextramer. The diagram in the lower part of the figure summarizes all results. The x-axis
shows the unique ID of each participating lab. The y-axis shows the percentage of NY-ESO-1 Dext+ of CD8+ T cells, as reported by the participants after staining of
the TERS batch at two independent time points (T1 and T2). Each symbol represents the result from one independent dextramer staining. The experiments were
performed by staining with an irrelevant dextramer at T1 (open circles) and T2 (indicated by “x”), with the specific NY-ESO-1 dextramer at T1 (closed circles) and T2
(indicated by “+”).
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assay protocols and the experimental setup. In the application phase,
the pre-tested TERS aliquots can be subsequently used to control assay
performance in a variety of ways, such as prior to assessing a series of
test samples (e.g. patient samples) as well as after the last test sample
has been run or in each experiment, on each day, or if required, for each
test item depending on the user's preferences.
TERS can be used to control and to detect technical sources of assay
variation as presented in a range of studies and proficiency panels for
most of the commonly used T-cell assays such HLA-peptide multimer
staining (Britten et al., 2009), intracellular cytokine flow cytometry
(Jaimes et al., 2011; Welters et al., 2012) and ELISpot assay (Chudley
et al., 2014; Janetzki and Britten, 2012). Furthermore, TERS can be
used for the validation and the day to day quality control of one T-cell
assay. Controlled assay performance makes it also possible to compare
results across centers leading to the desired harmonization of T cell
assays (van der Burg et al., 2011). The development of an easy to use
and easy to scale kit-based approach will allow the broad use of the
TERS technology enabling the labs to continuously produce TERS in-
house and will help to generate documented evidence of the validity of
assay-results generated throughout their biomarker programs and thus
may become a valuable tool to enhance the development of innovative
immune-therapies.
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